IS6174A - Nýjar afleiður og hliðstæður af galantamíni - Google Patents

Nýjar afleiður og hliðstæður af galantamíni

Info

Publication number
IS6174A
IS6174A IS6174A IS6174A IS6174A IS 6174 A IS6174 A IS 6174A IS 6174 A IS6174 A IS 6174A IS 6174 A IS6174 A IS 6174A IS 6174 A IS6174 A IS 6174A
Authority
IS
Iceland
Prior art keywords
galantamine
analogues
new derivatives
new
derivatives
Prior art date
Application number
IS6174A
Other languages
English (en)
Other versions
IS2287B (is
Inventor
Jordis Ulrich
Fröhlich Johannes
Treu Matthias
Hirnschall Manfred
Czollner Laszlo
Kälz Beate
Welzig Stefan
Original Assignee
Sanochemia Pharmazeutika Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Aktiengesellschaft filed Critical Sanochemia Pharmazeutika Aktiengesellschaft
Publication of IS6174A publication Critical patent/IS6174A/is
Publication of IS2287B publication Critical patent/IS2287B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS6174A 2000-03-31 2001-11-23 Nýjar afleiður og hliðstæður af galantamíni IS2287B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT5462000 2000-03-31
AT2382001 2001-02-15
PCT/AT2001/000082 WO2001074820A1 (de) 2000-03-31 2001-03-22 Neue derivate und analoga von galanthamin

Publications (2)

Publication Number Publication Date
IS6174A true IS6174A (is) 2001-11-23
IS2287B IS2287B (is) 2007-10-15

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6174A IS2287B (is) 2000-03-31 2001-11-23 Nýjar afleiður og hliðstæður af galantamíni

Country Status (26)

Country Link
US (2) US7166588B2 (is)
EP (1) EP1181294B1 (is)
JP (1) JP2003529602A (is)
CN (1) CN1380883A (is)
AT (1) ATE263171T1 (is)
AU (1) AU785385B2 (is)
BG (1) BG65134B1 (is)
BR (1) BR0105563A (is)
CA (1) CA2368966A1 (is)
CZ (1) CZ300160B6 (is)
DE (1) DE50101827D1 (is)
DK (1) DK1181294T3 (is)
ES (1) ES2215885T3 (is)
HK (2) HK1045990A1 (is)
HU (1) HUP0202233A3 (is)
IS (1) IS2287B (is)
MX (1) MXPA01012275A (is)
NO (1) NO326458B1 (is)
NZ (1) NZ516302A (is)
PL (1) PL202463B1 (is)
PT (1) PT1181294E (is)
RU (1) RU2241001C2 (is)
SI (1) SI1181294T1 (is)
SK (1) SK285909B6 (is)
TR (1) TR200400857T4 (is)
WO (1) WO2001074820A1 (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
EP1681291A1 (de) * 2002-03-25 2006-07-19 Sanochemia Pharmazeutika Aktiengesellschaft Verfahren zur Herstellung von Norgalanthamin, Ihren Isomeren, Salzen und Hydraten
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
ES2463715T3 (es) 2008-04-14 2014-05-29 Neurodyn Life Sciences Inc. Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
EP2583168B1 (en) 2010-06-15 2017-11-08 Ab Initio Technology LLC Dynamically loading graph-based computations
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
WO2015085152A1 (en) 2013-12-05 2015-06-11 Ab Initio Technology Llc Managing interfaces for dataflow graphs composed of sub-graphs
CA2959389A1 (en) 2014-09-02 2016-03-10 Ab Initio Technology Llc Compilation of graph-based program specifications with automated clustering of graph components based on the identification of particular data port connections
CN107145344B (zh) 2014-09-02 2020-12-04 起元科技有限公司 在基于图的程序中指定组件
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data
US12006301B1 (en) 2021-05-13 2024-06-11 Florida A&M University And synthesis of dual 5-HT1A and 5-HT7 receptor ligands

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
AU632458B2 (en) * 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
KR100352212B1 (ko) * 1994-10-21 2003-04-18 자노케미아 파마조이티카 악티엔게젤샤프트 4a,5,9,10,11,12-헥사히드로-6H-벤조푸로[3a,3,2-ef][2]벤즈아제핀유도체의제조방법
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
HK1045990A1 (en) 2002-12-20
SI1181294T1 (en) 2004-08-31
BR0105563A (pt) 2002-04-02
EP1181294A1 (de) 2002-02-27
NZ516302A (en) 2004-02-27
TR200400857T4 (tr) 2004-06-21
JP2003529602A (ja) 2003-10-07
ES2215885T3 (es) 2004-10-16
PT1181294E (pt) 2004-07-30
DK1181294T3 (da) 2004-08-02
SK17022001A3 (sk) 2003-02-04
AU785385B2 (en) 2007-03-29
NO326458B1 (no) 2008-12-08
MXPA01012275A (es) 2003-06-24
HUP0202233A2 (hu) 2002-11-28
EP1181294B1 (de) 2004-03-31
BG65134B1 (bg) 2007-03-30
US20070027138A1 (en) 2007-02-01
PL202463B1 (pl) 2009-06-30
WO2001074820A1 (de) 2001-10-11
AU4208501A (en) 2001-10-15
US7166588B2 (en) 2007-01-23
CZ300160B6 (cs) 2009-02-25
RU2241001C2 (ru) 2004-11-27
CN1380883A (zh) 2002-11-20
IS2287B (is) 2007-10-15
HUP0202233A3 (en) 2004-12-28
BG106155A (en) 2002-08-30
HK1049832A1 (zh) 2003-05-30
SK285909B6 (sk) 2007-10-04
PL352638A1 (en) 2003-09-08
CZ20014178A3 (cs) 2002-11-13
US20030199493A1 (en) 2003-10-23
NO20015857D0 (no) 2001-11-30
CA2368966A1 (en) 2001-10-11
NO20015857L (no) 2002-01-29
ATE263171T1 (de) 2004-04-15
DE50101827D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
SE0000540D0 (sv) New compounds
IS6174A (is) Nýjar afleiður og hliðstæður af galantamíni
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
CY1107634T1 (el) Φαρμακευτικη συνθεση
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
CY1111648T1 (el) Πολυαρυλκαρβοξαμιδια χρησιμα ως παραγοντες μειωσης λιπιδιων
ATE491703T1 (de) Phthalazinonderivate
CY1113648T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
DK1438306T3 (da) Derivater af UK-2A
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
DK1307181T3 (da) Hidtil ukendte sammensætninger af minoxidil
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
TW200510368A (en) Pharmaceutical compositions and combinations of novel non-imidazole compounds
DE60121461D1 (de) Kondensierte pyridoindolderivate
BR0213981A (pt) Fotoiniciadores difuncionais
DK1252293T3 (da) Kilde til levervæv
CY1105411T1 (el) Νεα παραγωγα πλευρομουτιλινης
CR8340A (es) Pirazolilcarboxanilidas n-sustituidas
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
BRPI0416678A (pt) pirazolpirimidinas
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
DK1644385T3 (da) Siliciumforbindelser og deres anvendelse